Nocturia in Patients With Parkinson's Disease
TLDR
Evaluated lower urinary tract (LUT) symptoms in patients with PD reporting nocturia using standardized validated questionnaires and bladder diaries and to assess the impact ofNocturia on quality of life and sleep.Abstract:
Background
Waking up from sleep more than once to pass urine, known as nocturia, is an important nonmotor symptom in Parkinson's disease (PD). Very little is known about the cause for nocturia. The aim of this work was to evaluate lower urinary tract (LUT) symptoms in patients with PD reporting nocturia using standardized validated questionnaires and bladder diaries and to assess the impact of nocturia on quality of life and sleep.
Methods
Twenty-three consecutive patients with PD (17 males, 6 females; mean age: 68.5 years; range, 50–85) referred to a specialist uro-neurology clinic reporting nocturia according to the International Continence Society definition were included. Patients measured their daily fluid intake, urinary output per void, and recorded these with the timing of voids on a 3-day bladder diary. Standardized questionnaires were used to assess LUT symptoms (Urinary Symptom Profile, International Prostate Symptom Score, and Qualiveen Short Form) and sleep quality (Parkinson's Disease Sleep Scale).
Results
Mean duration of PD was 10.1 years, and mean severity on H & Y scale was 3.0 (range, 1.0–5.0). Median duration of LUT symptoms was 6.0 years. Mean night-time urinary frequency was 3.5 (range, 1.0–7.3), and mean nocturnal maximum voided volume was 242 mL. Mean Nocturnal Polyuria Index (NPi) was 0.4 (range, 0.13–0.75), and 13 patients (56.5%) had nocturnal polyuria (NPi > 0.33). Patients with nocturnal polyuria reported more-severe LUT symptoms that impacted quality of life and sleep.
Conclusions
In this preliminary study, nocturnal polyuria seems to be common in patients with PD reporting nocturia and appears to affect quality of life and sleep, though this was not statistically significant. The bladder diary is an essential tool in the assessment of nocturia in patients with PD.read more
Citations
More filters
Journal ArticleDOI
Neurogenic Bladder: Epidemiology, Diagnosis, and Management.
TL;DR: An individualized, patient-tailored approach is required for the management of lower urinary tract dysfunction in this special population of patients with slowly progressive nontraumatic neurological disorders.
Journal ArticleDOI
Neurogenic lower urinary tract dysfunction: evaluation and management
TL;DR: Antimuscarinic agents are the first line treatment for patients with storage dysfunction and intradetrusor injection of onabotulinumtoxinA, which has been shown to be of benefit in patients with neurogenic detrusor overactivity (NDO), and neuromodulation.
Journal ArticleDOI
Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage?
TL;DR: Nocturia is one of the commonest nonmotor symptoms in Parkinson's disease (PD) and has a significant impact on quality of life both for patients and their carers.
Journal ArticleDOI
Treatment Options for Urogenital Dysfunction in Parkinson's Disease.
TL;DR: A patient-tailored approach is required for the optimal management of urogenital dysfunction in Parkinson’s disease (PD), and first line treatments include phosphodiesterase-5 inhibitors.
Journal ArticleDOI
Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care
Brent Bluett,Alexander Pantelyat,Irene Litvan,Farwa Ali,Diana Apetauerova,Danny Bega,Lisa Bloom,James H. Bower,Adam L. Boxer,Marian L. Dale,Rohit Dhall,Antoine Duquette,Hubert H. Fernandez,Jori Fleisher,Murray Grossman,Michael J. Howell,Diana R. Kerwin,Julie Leegwater-Kim,Christiane Lepage,Peter A. Ljubenkov,Martina Mancini,Nikolaus R. McFarland,Paolo Moretti,Erica Myrick,Pritika A. Patel,Laura S. Plummer,Federico Rodriguez-Porcel,Julio C. Rojas,Christos Sidiropoulos,Miriam Sklerov,Leonard L. Sokol,Paul J. Tuite,Lawren VandeVrede,Jennifer Wilhelm,Anne-Marie Wills,Tao Xie,Lawrence I. Golbe +36 more
TL;DR: Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death after an average of 7 years as discussed by the authors.
References
More filters
Journal ArticleDOI
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.
Michael J. Barry,Floyd J. Fowler,Michael P. O'Leary,Reginald C. Bruskewitz,Holtgrewe Hl,Winston K. Mebust,Abraham T.K. Cockett +6 more
TL;DR: The AUA symptom index for benign prostatic hyperplasia was developed and validated by a multidisciplinary measurement committee of the American Urological Association and is clinically sensible, reliable, valid and responsive.
Journal ArticleDOI
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease : The NMSQuest study
Kallol Ray Chaudhuri,Pablo Martinez-Martin,Anthony H.V. Schapira,Fabrizio Stocchi,Kapil D. Sethi,Per Odin,Richard G. Brown,W. C. Koller,Paolo Barone,Graeme Macphee,Linda Kelly,Martin Rabey,Doug MacMahon,Sue Thomas,William G. Ondo,David B. Rye,A Forbes,S. Tluk,Vandana Dhawan,A Bowron,Adrian J. Williams,C. W. Olanow +21 more
TL;DR: An international pilot study assessing feasibility, validity, and acceptability of a nonmotor questionnaire (NMSQuest) found NMS were highly significantly more prevalent across all disease stages and the number of symptoms correlated significantly with advancing disease and duration of disease.
Journal ArticleDOI
The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society.
Philip Van Kerrebroeck,Paul Abrams,David C. Chaikin,Jenny L Donovan,David Fonda,Simon Jackson,Poul Jennum,Theodore M. Johnson,Gunnar Lose,Anders Mattiasson,Gary L. Robertson,Jeffrey P. Weiss +11 more
Journal ArticleDOI
The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease
Kallol Ray Chaudhuri,Suvankar Pal,A. DiMarco,C. Whately-Smith,K. Bridgman,R. Mathew,F. R. Pezzela,Angus Forbes,Birgit Högl,Claudia Trenkwalder +9 more
TL;DR: This appears to be the first description of a simple bedside screening instrument for evaluation of sleep disturbances in Parkinson’s disease and a combination of subitems may help identify specific aspects of sleep disturbance, which may help target treatment.
Journal ArticleDOI
Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease
Ryuji Sakakibara,Hitoshi Shinotoh,Tomoyuki Uchiyama,Mitsufumi Sakuma,Masahide Kashiwado,Mitsuharu Yoshiyama,Takamichi Hattori +6 more
TL;DR: The findings show that bladder, bowel and sexual dysfunction are all prominent in patients with PD, and amelioration of pelvic organ dysfunction, particularly bowel dysfunction which most affects the quality of life, therefore should be a primary target in the treatment of patients withPD.